Safety study of crinecerfont for very young children with CAH
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be diagnosed with classic CAH caused by 21-hydroxylase deficiency (a specific genetic problem affecting hormone production)
- Child must weigh at least 4.5 kilograms (about 10 pounds)
- Child must have been taking hydrocortisone (a steroid replacement) for at least 3 months, with the same dose for at least 4 weeks before enrollment
- Child's newborn screening test must show either elevated 17-OHP levels or other findings that a pediatric specialist has evaluated and cleared
- Child cannot have other forms of CAH or other conditions requiring daily steroid therapy
- Child cannot have other serious medical conditions or chronic diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This study aims to improve the transition from pediatric to adult care for young people with congenital adrenal hyperplasia (CAH). It will test a special transition program and may help make the shift to adult care smoother and more supported.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.